DisTinGuish
Phase 2 Terminated
247 enrolled 38 charts
Lithium
Phase 1 Terminated
2 enrolled
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Phase 2 Terminated
5 enrolled 11 charts
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Phase 2 Terminated
29 enrolled
PECORINO
Phase 2 Terminated
69 enrolled
repeat
Phase 2 Terminated
15 enrolled
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Phase 1/2 Terminated
2 enrolled 9 charts
Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
Phase 3 Terminated
171 enrolled
A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer
Phase 2 Terminated
27 enrolled
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma
Phase 2 Terminated
4 enrolled
mEGA
Phase NA Terminated
13 enrolled 6 charts
FluoHeart
Phase 2 Terminated
20 enrolled
Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer
Phase 2 Terminated
10 enrolled 7 charts
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
Phase 2 Terminated
8 enrolled 9 charts
Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer
Phase 2 Terminated
29 enrolled
Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer
Phase 1 Terminated
3 enrolled
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
Phase 1/2 Terminated
50 enrolled
RILOMET-1
Phase 3 Terminated
609 enrolled
XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)
Phase 3 Terminated
42 enrolled
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Phase 1 Terminated
16 enrolled
Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer
Phase 1/2 Terminated
1 enrolled
S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery
Phase 2 Terminated
7 enrolled 7 charts